The potential effects of BRAFV600E-inhibitors on the immune response have not been investigated in thyroid cancer because all previous studies using human thyroid cancer cells have used immunocompromised mice and novel genetically engineered mice with BRAF tumors rarely show aggressive behavior [22]. Here, BRAF is linked to thyroid cancer.